Medicare proposes coverage limits for anti-anemia drugs

Medicare has proposed new restrictions on what it will cover for cancer patients prescribed anti-anemia drugs known as erythropoiesis-stimulating agents because of ties to death risks. Amgen makes Aranesp and Epogen and Johnson & Johnson makes Procrit for treating the problem, and they are expected to suffer the hardest hit if the Medicare proposal becomes final.

View Full Article in:

CNNMoney · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director Quality Improvement
Molina Healthcare of Texas
San Antonio, TX
Senior Medical Director
Network Health
Medford, MA
SVP/Head of Health Plans and Managed Care
Avalere Health
Washington, DC
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR